Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raseglurant Monotherapy in GERD
NCT00820079Phase 2Completed
- Sponsor
- Addex Therapeutics Ltd
- Start
- Dec 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of raseglurant in gastroesophageal reflux disease (GERD), sponsored by Addex Therapeutics Ltd. Started Dec 2008; status: completed.
02
Drugs
raseglurant
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00820079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820079.